15 September 2026
Bitrobius Genetics and the University of Cambridge secure a £700k ARIA grant to develop mitochondrial gene delivery technologies
Macclesfield, UK, 14th September 2026 – Bitrobius Genetics Ltd, a pioneering genetic medicines company, has been awarded a grant of £700k ($940k) from the UK’s Advanced Research + Invention Agency (ARIA), to enable its core technology to be applied to genetic modification of...
8 September 2026
INFEX Therapeutics presents new Phase IIa data for RESP-X providing further evidence on exploratory efficacy endpoints supporting progression to later stage development
Alderley Park, Cheshire, U.K. – 8 September 2026 – Infex Therapeutics, a leading anti-infectives specialist, today announced new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB)...
26 August 2026
Lenis Group and Proveca announce exclusive strategic partnership to commercialise Aqumeldi® in Central and Eastern Europe
This press release is intended for investors only. Partnership aims to expand access to age-appropriate treatment for children with heart failure across 17 markets … LJUBLJANA, Slovenia and MANCHESTER, United Kingdom, 20th August 2026, Lenis farmacevtika, a specialist...
24 August 2026
Biofortuna completes acquisition of Colibri Scientific Limited
Biofortuna Limited, the specialist laboratory services and diagnostic CDMO, has completed the acquisition of Colibri Scientific Limited. The move underlines Biofortuna’s commitment to supporting life-changing research and development across the healthcare and life sciences...
19 August 2026
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
Alderley Park, Cheshire, U.K. – 19 August 2026 – Infex Therapeutics, a leading anti-infectives specialist, today announced that new Phase IIa study data for RESP-X (INFEX702), its first-in-class anti-virulence monoclonal antibody therapy in development for NCFB patients...
10 August 2026
Proveca receives positive CHMP opinion for Sialanar® (Glycopyrronium) orodispersible tablets (ODT), expanding choice in the management of severe sialorrhoea.
This press release is intended for investors only. … Positive opinion supports an innovative, orodispersible tablet formulation designed to provide an additional licensed treatment option for children affected by severe sialorrhoea. Proveca has announced that the Committee for...
21 July 2026
Proveca signs exclusive licensing agreement with LinDo K.K. for the development and commercialisation of Sialanar® in Japan
This press release is intended for investors only. Partnership expands access to a licensed paediatric treatment for severe sialorrhoea and supports delivery of innovative medicines to children in Japan … MANCHESTER, UK and TOKYO, JAPAN, July 15th, 2026 – Proveca Ltd.
22 June 2026
Oxford BioTherapeutics’ third partnered programme with Boehringer Ingelheim enters the clinic and its first (Obrixtamig) advances to Phase 3
… • First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development … • Obrixtamig reaches late-stage development triggering milestone payment … • Continued clinical...
21 May 2026
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
• Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa) • Secondary objectives met with no immunogenicity observed, favorable PK, and lung deposition supporting convenient...
13 May 2026
INFEX Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
Alderley Park, Cheshire, U.K. – 12 May 2026, Infex Therapeutics, a leading anti-infectives specialist, announces it has secured £4.3 million in funding led by prominent British venture capitalist Jon Moulton, with participation from the GM&C Life Sciences Fund (managed by...